Home › Ewing Sarcoma › Florida
Ewing Sarcoma clinical trials in Florida
7 studies for Ewing Sarcoma are looking for participants at sites in Florida.
Cities in Florida
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
- University of Florida, Gainesville
- Nemours Jacksonville, Jacksonville
- University of Miami, Miami
- and 2 more
RecruitingPhase 1
Ages 1 and older · All sexes · Updated Sep 25, 2026 · NCT07194044Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Johns Hopkins All Children's Hospital ( Site 1025), St. Petersburg
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- University of Florida, Gainesville
- Nicklaus Children's Hospital, Miami
- Arnold Palmer Hospital for Children, Orlando
- and 2 more
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- University of Florida, Gainesville
- Nicklaus Children's Hospital, Miami
- Arnold Palmer Hospital for Children, Orlando
- and 1 more
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
- St. Joseph's Children's Hospital, Tampa
RecruitingPhase 2
Ages 0 to 50 · All sexes · Updated Jul 9, 2026 · NCT07321912Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
- University of Florida, Gainesville
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Jun 30, 2026 · NCT06625190Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Johns Hopkins All Children's Hospital, St. Petersburg
RecruitingPhase 1/2
Ages 2 to 30 · All sexes · Updated Feb 3, 2026 · NCT05734066From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.